Migraine Excellence Hub

Excellence Forum

Leaders in the field share expert insights and institutional best practices.

Conference Coverage

Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
Conference Coverage
Conference Coverage
12/15/2025
Kate Young
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
12/15/2025
CONFERENCE COVERAGE
CONFERENCE COVERAGE
12/12/2025
Anthony Calabro, MA
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
12/12/2025
CONFERENCE COVERAGE
CONFERENCE COVERAGE
12/12/2025
Anthony Calabro, MA
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
12/12/2025
CONFERENCE COVERAGE
CONFERENCE COVERAGE
12/12/2025
Anthony Calabro, MA
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
12/12/2025
CONFERENCE COVERAGE
CONFERENCE COVERAGE
12/12/2025
Anthony Calabro, MA
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
12/12/2025